Drug Trial News

RSS

Van Andel Institute and Cure Parkinson's extend major Parkinson's drug trial initiative

Van Andel Institute and Cure Parkinson's have renewed a funding agreement to support the International Linked Clinical Trials Program, the world's largest drug repurposing clinical trial initiative for Parkinson's disease.

10 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Landmark RSI trial reshapes sedative selection for emergency airway management

Doctors treating seriously ill patients in an emergency setting may want to give the sedative etomidate, rather than ketamine, while placing a breathing tube, according to a randomized trial published in the New England Journal of Medicine.

9 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

9 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

Targeted approach of immunotherapy improves sepsis outcomes

Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition.

8 Dec 2025

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.

8 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

Exa-cel shows complete success in early pediatric trials for sickle cell disease and beta-thalassemia

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12.

6 Dec 2025

$New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer$

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.

5 Dec 2025

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

5 Dec 2025

Drug Trial News

Van Andel Institute and Cure Parkinson's extend major Parkinson's drug trial initiative

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Landmark RSI trial reshapes sedative selection for emergency airway management

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

Combination therapy may boost survival for people with aggressive lymphoma

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

Targeted approach of immunotherapy improves sepsis outcomes

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

New trial shows major survival gains with epcoritamab added to standard R2 therapy

Exa-cel shows complete success in early pediatric trials for sickle cell disease and beta-thalassemia

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News